

# A Review of the Development and Validation of Bioanalytical Methods

Ashish Kumar<sup>1</sup> and Dr. Dharendra Babji Sanghai<sup>2</sup>

Research Scholar, Department of Pharmacy<sup>1</sup>

Associate Professor, Department of Pharmacy<sup>2</sup>

Sunrise University, Alwar, Rajasthan, India

**Abstract:** This review article often uses bioanalytical techniques to assess pharmaceuticals and their metabolites in plasma matrices; these approaches must be used in clinical research including both humans and nonhuman subjects. An essential stage in the estimate and interpretation of bioequivalence, pharmacokinetic, and toxicokinetic studies is the use of the bioanalytical technique for the quantitative evaluation of medicines and their metabolites in biological medium. The three main bioanalytic tasks are method development, method validation, and sample analysis. To determine how much the environment, the matrix, or procedural factors might affect the estimate of analyte in the matrix from the time of set up to the time of analysis, each step of the process must be examined. Techniques for bioanalyzing pharmaceuticals in the body include high pressure liquid chromatography (HPLC) and liquid chromatography combined with double mass spectrometry (LCMS-MS). Each instrument has certain advantages and disadvantages. For the bioanalysis of both small and large compounds, gas chromatography and LC/MS/MS have been the most used chromatographic techniques. A few often used metrics include linearity, accuracy, precision, selectivity, sensitivity, repeatability, and stability. It is suggested that we include some information on the creation and verification of bioanalytical procedures in this review research. These details will help with quality control since they allow us to identify the medicine, its concentration, and its metabolite.

**Keywords:** Clinical and nonclinical study, Method development, Validation parameter.

## REFERENCES

- [1]. Thompson M, Ellison SL, Wood R. Harmonized guidelines for single laboratory validation of method of analysis. *Pure Appl Chem* 2008;74(5):835-55.
- [2]. Wood R. How to validate analytical methods. *Trends Analyt Chem* 2005;18:624-32.
- [3]. Chiu ML, Lawi W, Snyder ST, Wong PK, Liao JC, Gau V. Matrix effects: A challenge toward automation of molecular analysis. *J Assoc Lab Autom* 2010;15:233-42.
- [4]. Reid E, Wilson ID. Methodological survey in biochemistry and analysis. *Analysis for Drug and Metabolites, Including Anti-Infective Agents*. Vol. 20. Cambridge, England: Royal Society of Chemistry; 1990. p. 1-57.
- [5]. Surendra B, DeStefano A. Key elements of bioanalytical method validation for small molecules. *AAPS J* 2007;9(1):109-14.
- [6]. McDowall RD. The role of laboratory information management systems LIMS in analytical method validation. *Anal Chim Acta* 2007;54:149-58.
- [7]. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. *J Pharm Biomed Anal* 2001;24(5-6):723-53.
- [8]. Puluído A, Ruusanches I, Boque R, Rius FX. Uncertainty of results in routine qualitative analysis in analytical chemistry. *J Pharm Biomed Anal* 2005;22:647-54.
- [9]. Kallner A. Quality specifications based on the uncertainty of measurement. *Scand J Clin Lab Invest* 1999;59(7):513-6.
- [10]. Rao KR, Kumar KS. Bioanalytical method validation-A quality assurance auditor view point. *J Pharm Sci Res* 2009;1(3):1-10.

- [11]. Lang JR, Bolton S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry--1. Experimental considerations. *J Pharm Biomed Anal* 1991;9(5):357-61.
- [12]. Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. *J Chromatogr B Biomed Sci Appl* 1997;689(1):175-80.
- [13]. Shah VP. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical method validation. *AAPS J* 2007;9(1):43-7.
- [14]. Buick AR, Doig MV, Jeal SC, Land GS, McDowall RD. Method validation in the bioanalytical laboratory. *J Pharm Biomed Anal* 1990;8(8-12):629-37.
- [15]. Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. *Pharm Methods* 2010;1(1):25-38.
- [16]. Jhang JS, Chang CC, Fink DJ, Kroll MH. Evaluation of linearity in the clinical laboratory. *Arch Pathol Lab Med* 2004;128(1):44-8.
- [17]. Mark H. Application of improved procedure for testing linearity of analytical method to pharmaceutical analysis. *J Pharm Biomed Anal* 2003;33(1):7-20.
- [18]. Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD. Validation of bioanalytical chromatographic methods. *J Pharm Biomed Anal* 1998;17(2):193-218.
- [19]. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Vol. 13. Rockville, MD: U.S Department of Health and Human Services, Food and Drug Administration; 2001. p. 385-94.
- [20]. Wells DA. High throughput bioanalytical sample preparation: Methods and automation strategies. *Progress in Pharmaceutical and Biomedical Analysis*. Vol. 30. Amsterdam, London: Elsevier; 2003. p. 610.
- [21]. Karnes HT, Shiu G, Shah VP. Validation of bioanalytical methods. *Pharm Res* 1991;8(4):421-6.
- [22]. Kringle RO. An assessment of the 4-6-20 rule of acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. *Pharm Res* 1994;11(4):556-60.
- [23]. Wieling J, Hendriks G, Tamminga WJ, Hempenius J, Mensink CK, Oosterhuis B, et al. Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma. *J Chromatogr A* 1996;730(1-2):381-94.
- [24]. Kringle R, Hoffman D. Stability methods for assessing stability of compounds in whole blood for clinical bioanalysis. *Drug Inf J* 2001;35:1261-70.
- [25]. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. *AAPS J* 2007;9(2):E260-7.
- [26]. Singh PS, Shah G. Analytical method development and validation. *J Pharm Res* 2011;4(5):2330-2.
- [27]. Dadgar D, Burnett PE. Issues in evaluation of bioanalytical method selectivity and drug stability. *J Pharm Biomed Anal* 1995;14(1-2):23-31.
- [28]. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW, et al. Workshop on bioanalytical methods validation for macromolecules: Summary report. *Pharm Res* 2001;18(9):1373-83.
- [29]. Hubert H, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, et al. The SFSTP guide on the validation of chromatographic methods for drug analysis: From the Washington Conference to the laboratory. *Anal Chim Acta* 1999;391:45-55.
- [30]. Timm U, Wall M, Dell D. A new approach for dealing with the stability of drugs in biological fluids. *J Pharm Sci* 1985;74(9):972-7.
- [31]. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. *AAPS J* 2007;9(2):E117-22.
- [32]. Braggio S, Barnaby RJ, Grossi P, Cugola M. A strategy for validation of bioanalytical methods. *J Pharm Biomed Anal* 1996;14(4):375-88.
- [33]. James CA, Breda M, Frigerio E. Bioanalytical method validation: Arisk-based approach? *J Pharm Biomed Anal* 2004;35(4):887-93.

- [34]. Boulanger B, Chiap P, Dewe W, Crommen J, Hubert P. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: Progresses and limitations. J Pharm Biomed Anal 2005;32(4-5):753-65.